NCIt definition : A tetravalent, bispecific antibody directed against both the tumor-associated antigen
(TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily
member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating
and antineoplastic activities. Upon administration, cizutamig binds to both CD3 on
cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates
and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing
of BCMA-expressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand
(APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor
(TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival;
it is found on the surfaces of plasma cells and overexpressed on malignant plasma
cells. In cizutamig, the two antigen-binding fragments (Fabs) are fused directly in
a crisscross orientation resulting in four active and independent antigen binding
sites.;
Semantic type(s)